메뉴 건너뛰기




Volumn 12, Issue 19, 2006, Pages 2425-2435

Pharmacogenetics of antithrombotic drugs

Author keywords

Antithrombotic drugs; Cardiovascular; Genetic polymorphism; Pharmacogenetics; Pharmacogenomics; Thrombosis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOPIDOGREL; COUMARIN; CYTOCHROME P450; EPTIFIBATIDE; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MENADIONE EPOXIDE; ORBOFIBAN; PHENPROCOUMON; PLACEBO; PRAVASTATIN; PROSTAGLANDIN SYNTHASE; PROTHROMBIN; STROMELYSIN; THROMBOCYTE RECEPTOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

EID: 33745756526     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698963     Document Type: Review
Times cited : (10)

References (115)
  • 1
    • 0037421590 scopus 로고    scopus 로고
    • Pharmacogenomics. Drug disposition, drug targets, and side effects
    • Evans WE, McLeod HL. Pharmacogenomics. Drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
    • (2003) N Engl J Med , vol.348 , pp. 538-549
    • Evans, W.E.1    McLeod, H.L.2
  • 2
    • 0036628637 scopus 로고    scopus 로고
    • Pharmacogenetics and cardiovascular disease: Impact on drug response and applications to disease management
    • Humma LM, Terra SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am J Health Syst Pharm 2002, 59: 1241-52.
    • (2002) Am J Health Syst Pharm , vol.59 , pp. 1241-1252
    • Humma, L.M.1    Terra, S.G.2
  • 3
    • 0026704175 scopus 로고
    • Prostaglandin endoperoxide synthase. The aspirin acetylation region
    • Shimokawa T, Smith WI. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992; 267: 12387-92.
    • (1992) J Biol Chem , vol.267 , pp. 12387-12392
    • Shimokawa, T.1    Smith, W.I.2
  • 4
    • 8344231455 scopus 로고    scopus 로고
    • Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance
    • Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , pp. 1980-1987
    • Cattaneo, M.1
  • 6
    • 0036846748 scopus 로고    scopus 로고
    • Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance
    • McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-5.
    • (2002) Thromb Haemost , vol.88 , pp. 711-715
    • McKee, S.A.1    Sane, D.C.2    Deliargyris, E.N.3
  • 7
    • 0141851094 scopus 로고    scopus 로고
    • Aspirin resistance: Definition, mechanisms and clinical read-outs
    • Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
    • (2003) J Thromb Haemost , vol.1 , pp. 1710-1713
    • Patrono, C.1
  • 9
    • 0037256309 scopus 로고    scopus 로고
    • Genetic variation in cyclooxygenase 1: Effects on response to aspirin
    • Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
    • (2003) Clin Pharmacol Ther , vol.3 , pp. 122-130
    • Halushka, M.K.1    Walker, L.P.2    Halushka, P.V.3
  • 10
    • 12844269195 scopus 로고    scopus 로고
    • Biological assessment of aspirin efficacy on healthy individuals: Heterogeneous response or aspirin failure?
    • Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-80.
    • (2005) Stroke , vol.36 , pp. 276-280
    • Gonzalez-Conejero, R.1    Rivera, J.2    Corral, J.3    Acuna, C.4    Guerrero, J.A.5    Vicente, V.6
  • 11
    • 1042268032 scopus 로고    scopus 로고
    • Cyclooxygenase-2 expression and inhibition in atherothrombosis
    • Cipollone F, Rocca B, Patrono, C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-55.
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , pp. 246-255
    • Cipollone, F.1    Rocca, B.2    Patrono, C.3
  • 12
    • 18444377050 scopus 로고    scopus 로고
    • Cyclooxygenase-2 expression is induced during human megakaryopoyesis and characterizes newly formed platelets
    • Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoyesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 7634-7639
    • Rocca, B.1    Secchiero, P.2    Ciabattoni, G.3    Ranelletti, F.O.4    Catani, L.5    Guidotti, L.6
  • 14
    • 0036790471 scopus 로고    scopus 로고
    • Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response
    • Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-6.
    • (2002) Arterioscler Thromb Vasc Biol , vol.22 , pp. 1631-1636
    • Papafili, A.1    Hill, M.R.2    Brull, D.J.3    McAnulty, R.J.4    Marshall, R.P.5    Humphries, S.E.6
  • 15
    • 0026767437 scopus 로고
    • The molecular biology of human platelet proteins
    • Kunicki TJ, Newman PJ. The molecular biology of human platelet proteins. Blood 1992; 80: 1396-404.
    • (1992) Blood , vol.80 , pp. 1396-1404
    • Kunicki, T.J.1    Newman, P.J.2
  • 21
    • 0033586430 scopus 로고    scopus 로고
    • Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation
    • Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982-3.
    • (1999) Lancet , vol.353 , pp. 982-983
    • Undas, A.1    Sanak, M.2    Musial, J.3    Szczeklik, A.4
  • 22
    • 0033761053 scopus 로고    scopus 로고
    • Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa
    • Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2002; 110: 965-7.
    • (2002) Br J Haematol , vol.110 , pp. 965-967
    • Szczeklik, A.1    Undas, A.2    Sanak, M.3    Frolow, M.4    Wegrzyn, W.5
  • 23
    • 0031586491 scopus 로고    scopus 로고
    • Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
    • Walter DH, Schächinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217-9.
    • (1997) Lancet , vol.350 , pp. 1217-1219
    • Walter, D.H.1    Schächinger, V.2    Elsner, M.3    Dimmeler, S.4    Zeiher, A.M.5
  • 25
    • 0034919959 scopus 로고    scopus 로고
    • Platelet polymorphisms in thrombotic disorders
    • Santoso S. Platelet polymorphisms in thrombotic disorders. Transfus Clin Biol 2001; 8: 261-6.
    • (2001) Transfus Clin Biol , vol.8 , pp. 261-266
    • Santoso, S.1
  • 26
    • 0034254319 scopus 로고    scopus 로고
    • The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
    • Ariëns RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
    • (2000) Blood , vol.96 , pp. 988-995
    • Ariëns, R.A.S.1    Philippou, H.2    Nagaswami, C.3    Weisel, J.W.4    Lane, D.A.5    Grant, P.J.6
  • 28
    • 0038740548 scopus 로고    scopus 로고
    • Role of Factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction
    • Roldán V, Corral J, Marin F, Rivera J, Pineda J, Gonzalez-Conejero R, et al. Role of Factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol 2003; 91: 1242-5.
    • (2003) Am J Cardiol , vol.91 , pp. 1242-1245
    • Roldán, V.1    Corral, J.2    Marin, F.3    Rivera, J.4    Pineda, J.5    Gonzalez-Conejero, R.6
  • 29
    • 0242348804 scopus 로고    scopus 로고
    • Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk
    • Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31
    • (2003) Lancet , vol.361 , pp. 1424-1431
    • Lim, B.C.1    Ariens, R.A.2    Carter, A.M.3    Weisel, J.W.4    Grant, P.J.5
  • 30
    • 0037422559 scopus 로고    scopus 로고
    • Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism
    • Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 17-20.
    • (2003) Circulation , vol.107 , pp. 17-20
    • Undas, A.1    Sydor, W.J.2    Brummel, K.3    Musial, J.4    Mann, K.G.5    Szczeklik, A.6
  • 32
    • 1642453779 scopus 로고    scopus 로고
    • Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    • Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
    • (2004) Circulation , vol.109 , pp. 166-171
    • Lau, W.C.1    Gurbel, P.A.2    Watkins, P.B.3    Neer, C.J.4    Hopp, A.S.5    Carville, D.G.M.6
  • 33
    • 11144357704 scopus 로고    scopus 로고
    • PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation
    • Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15: 89-93.
    • (2004) Blood Coagul Fibrinolysis , vol.15 , pp. 89-93
    • Angiolillo, D.J.1    Fernández-Ortiz, A.2    Bernardo, E.3    Alfonso, F.4    Sabate, M.5    Fernandez, C.6
  • 34
    • 0032173427 scopus 로고    scopus 로고
    • Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 betal density
    • Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 betal density. Blood 1998; 92: 2382-8.
    • (1998) Blood , vol.92 , pp. 2382-2388
    • Kritzik, M.1    Savage, B.2    Nugent, D.J.3    Santoso, S.4    Ruggeri, Z.M.5    Kunicki, T.J.6
  • 35
    • 0001218842 scopus 로고    scopus 로고
    • Association of two silent polymorphisms of platelet glycoprotein Ia/lIa receptor with risk of myocardial infarction: A case-control study
    • Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/lIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-4.
    • (1999) Lancet , vol.353 , pp. 351-354
    • Moshfegh, K.1    Wuillemin, W.A.2    Redondo, M.3    Lammle, B.4    Beer, J.H.5    Liechti-Gallati, S.6
  • 36
    • 3142512587 scopus 로고    scopus 로고
    • 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment
    • Angiolillo DJ, Fenández-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, et al. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004, 15: 427-33.
    • (2004) Blood Coagul Fibrinolysis , vol.15 , pp. 427-433
    • Angiolillo, D.J.1    Fenández-Ortiz, A.2    Bernardo, E.3    Ramirez, C.4    Escaned, J.5    Moreno, R.6
  • 37
    • 0042859862 scopus 로고    scopus 로고
    • Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
    • Fontana P, Dupont A, Grandille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
    • (2003) Circulation , vol.108 , pp. 989-995
    • Fontana, P.1    Dupont, A.2    Grandille, S.3    Bachelot-Loza, C.4    Reny, J.L.5    Aiach, M.6
  • 38
    • 0034127259 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
    • Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103-15.
    • (2000) J Am Coll Cardiol , vol.5 , pp. 1103-1115
    • Lincoff, A.M.1    Califf, R.M.2    Topol, E.J.3
  • 40
    • 0344665785 scopus 로고    scopus 로고
    • Comparative pharmacology of Gp IIb/IIIa antagonists
    • Schrör K, Weber AA. Comparative pharmacology of Gp IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-86.
    • (2003) J Thromb Thrombolysis , vol.15 , pp. 71-86
    • Schrör, K.1    Weber, A.A.2
  • 42
    • 0036796343 scopus 로고    scopus 로고
    • No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors
    • Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharrf RE, et al. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002; 12: 581-3.
    • (2002) Pharmacogenetics , vol.12 , pp. 581-583
    • Weber, A.A.1    Jacobs, C.2    Meila, D.3    Weber, S.4    Zotz, R.B.5    Scharrf, R.E.6
  • 43
    • 0035872215 scopus 로고    scopus 로고
    • Effect of the P1A2 alloantigen on the firriction of b3-integrins in platelets
    • Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect of the P1A2 alloantigen on the firriction of b3-integrins in platelets. Blood 2001; 97: 3093-9.
    • (2001) Blood , vol.97 , pp. 3093-3099
    • Bennett, J.S.1    Catella-Lawson, F.2    Rut, A.R.3    Vilaire, G.4    Qi, W.5    Kapoor, S.C.6
  • 44
    • 1642434016 scopus 로고    scopus 로고
    • P1A polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction
    • Gorchakova O, Koch W, Mehili J, von Becherath N, Schwaiger M, Schömig A, et al. P1A polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. Thromb Haemost 2004; 91: 141-5.
    • (2004) Thromb Haemost , vol.91 , pp. 141-145
    • Gorchakova, O.1    Koch, W.2    Mehili, J.3    von Becherath, N.4    Schwaiger, M.5    Schömig, A.6
  • 45
    • 2342436814 scopus 로고    scopus 로고
    • Oral GPIIb/IIIa antagonists: What went wrong?
    • Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 2004; 10: 1587-96.
    • (2004) Curr Pharm Des , vol.10 , pp. 1587-1596
    • Cox, D.1
  • 46
    • 0035760865 scopus 로고    scopus 로고
    • Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral OPIIb/IIIa antagonist in patients with unstable coronary syndromes
    • O'Connor FF, Shields DC, Fizgerald A, Cannon CP, Braunwald E, Fizgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral OPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256-60.
    • (2001) Blood , vol.98 , pp. 3256-3260
    • O'Connor, F.F.1    Shields, D.C.2    Fizgerald, A.3    Cannon, C.P.4    Braunwald, E.5    Fizgerald, D.J.6
  • 47
    • 0036366737 scopus 로고    scopus 로고
    • The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to II b/IIIa antagonist
    • Shields DC, Fitzgerald AP, O'Neil PA, Muckian C, Kenny D, Moran B, et al. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to II b/IIIa antagonist. Pharmacogenomics J 2002; 2: 182-90.
    • (2002) Pharmacogenomics J , vol.2 , pp. 182-190
    • Shields, D.C.1    Fitzgerald, A.P.2    O'Neil, P.A.3    Muckian, C.4    Kenny, D.5    Moran, B.6
  • 48
    • 0032212143 scopus 로고    scopus 로고
    • Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIb beta 3) inhibitors
    • Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIb beta 3) inhibitors. Blood 1998; 92: 3240-9.
    • (1998) Blood , vol.92 , pp. 3240-3249
    • Peter, K.1    Schwarz, M.2    Ylanne, J.3    Kohler, B.4    Moser, M.5    Nordt, T.6
  • 49
    • 0034332785 scopus 로고    scopus 로고
    • Evidence of platelet activation during treatment with a GP IIb/IIIa antagonist in patients presenting with acute coronary syndromes
    • Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GP IIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9.
    • (2000) J Am Coll Cardiol , vol.36 , pp. 1514-1519
    • Cox, D.1    Smith, R.2    Quinn, M.3    Theroux, P.4    Crean, P.5    Fitzgerald, D.J.6
  • 50
    • 0036544668 scopus 로고    scopus 로고
    • Low incidence of paradoxical platelet activation by glycoprotein II b/IIIa inhibitors
    • Weber AA, Meila D, Jacobs C, Weber S, Kelm M, Strauer BE, et al. Low incidence of paradoxical platelet activation by glycoprotein II b/IIIa inhibitors. Thromb Res 2002; 106: 25-9.
    • (2002) Thromb Res , vol.106 , pp. 25-29
    • Weber, A.A.1    Meila, D.2    Jacobs, C.3    Weber, S.4    Kelm, M.5    Strauer, B.E.6
  • 51
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
    • (1999) Lancet , vol.353 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.L.3    Daly, A.K.4
  • 52
    • 0036624883 scopus 로고    scopus 로고
    • Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol
    • Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-9.
    • (2002) Blood , vol.99 , pp. 4237-4239
    • Hermida, J.1    Zarza, J.2    Alberca, I.3    Montes, R.4    Lopez, M.L.5    Molina, E.6
  • 53
    • 0036854237 scopus 로고    scopus 로고
    • Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation
    • Tàssies D, Freire C, Pijoan J, Maragall S, Monteagudo J, Ordinas A, et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87: 1185-91.
    • (2002) Haematologica , vol.87 , pp. 1185-1191
    • Tàssies, D.1    Freire, C.2    Pijoan, J.3    Maragall, S.4    Monteagudo, J.5    Ordinas, A.6
  • 54
    • 3543028046 scopus 로고    scopus 로고
    • The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
    • Visser LE, van Schaik RHN, van Vliet M, Trienekens PH, De Smet PAGM, Vulto AG, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-6.
    • (2004) Thromb Haemost , vol.92 , pp. 61-66
    • Visser, L.E.1    van Schaik, R.H.N.2    van Vliet, M.3    Trienekens, P.H.4    De Smet, P.A.G.M.5    Vulto, A.G.6
  • 55
    • 10744229776 scopus 로고    scopus 로고
    • Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S- phenprocoumon in healthy volunteers
    • Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S- phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14: 19-26.
    • (2004) Pharmacogenetics , vol.14 , pp. 19-26
    • Kirchheiner, J.1    Ufer, M.2    Walter, E.C.3    Kammerer, B.4    Kahlich, R.5    Meisel, C.6
  • 57
    • 0034051119 scopus 로고    scopus 로고
    • Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus
    • Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9.
    • (2000) Pharmacogenetics , vol.10 , pp. 85-89
    • Imai, J.1    Ieiri, I.2    Mamiya, K.3    Miyahara, S.4    Furuumi, H.5    Nanba, E.6
  • 58
    • 0034921210 scopus 로고    scopus 로고
    • Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
    • Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-7.
    • (2001) Mol Pharmacol , vol.60 , pp. 382-387
    • Dickmann, L.J.1    Rettie, A.E.2    Kneller, M.B.3    Kim, R.B.4    Wood, A.J.5    Stein, C.M.6
  • 59
    • 4544288090 scopus 로고    scopus 로고
    • Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    • Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-9.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 210-219
    • Zhao, F.1    Loke, C.2    Rankin, S.C.3    Guo, J.Y.4    Lee, H.S.5    Wu, T.S.6
  • 60
    • 0037374422 scopus 로고    scopus 로고
    • Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
    • Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 253-263
    • Takahashi, H.1    Wilkinson, G.R.2    Caraco, Y.3    Muszkat, M.4    Kim, R.B.5    Kashima, T.6
  • 62
    • 10744228888 scopus 로고    scopus 로고
    • Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
    • Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
    • (2004) Nature , vol.427 , pp. 537-541
    • Rost, S.1    Fregin, A.2    Ivaskevicius, V.3    Conzelmann, E.4    Hörtnagel, K.5    Pelz, H.J.6
  • 63
    • 12344331747 scopus 로고    scopus 로고
    • Pharmacodynamic resistance to warfarin associated with a Va166Met substitution in vitamin K epoxide reductase complex subunit 1
    • Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EGD, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Va166Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 23-6.
    • (2005) Thromb Haemost , vol.93 , pp. 23-26
    • Harrington, D.J.1    Underwood, S.2    Morse, C.3    Shearer, M.J.4    Tuddenham, E.G.D.5    Mumford, A.D.6
  • 64
    • 11244332058 scopus 로고    scopus 로고
    • A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
    • D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105: 645-9.
    • (2005) Blood , vol.105 , pp. 645-649
    • D'Andrea, G.1    D'Ambrosio, R.L.2    Di Perna, P.3    Chetta, M.4    Santacroce, R.5    Brancaccio, V.6
  • 65
    • 0029839951 scopus 로고    scopus 로고
    • A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism
    • Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996, 98: 1619-25.
    • (1996) J Clin Invest , vol.98 , pp. 1619-1625
    • Chu, K.1    Wu, S.M.2    Stanley, T.3    Stafford, D.W.4    High, K.A.5
  • 66
    • 8544283812 scopus 로고    scopus 로고
    • Missense mutations at ALA-10 in the factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy
    • Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Müller CR, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 2404.
    • (1997) Br J Haematol , vol.98 , pp. 240-244
    • Oldenburg, J.1    Quenzel, E.M.2    Harbrecht, U.3    Fregin, A.4    Kress, W.5    Müller, C.R.6
  • 68
    • 1642335299 scopus 로고    scopus 로고
    • Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity
    • Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-5.
    • (2004) Blood , vol.103 , pp. 2630-2635
    • Shikata, E.1    Ieiri, I.2    Ishiguro, S.3    Aono, H.4    Inoue, K.5    Koide, T.6
  • 70
    • 4644242157 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia: Recognition, treatment and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 311S-37S.
    • (2004) Chest , vol.126 , Issue.3 SUPPL.
    • Warkentin, T.E.1    Greinacher, A.2
  • 71
    • 0032170569 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia: New insights into the impact of the FcγIIa-R-H131 polymorphism
    • Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, et al. Heparin-induced thrombocytopenia: new insights into the impact of the FcγIIa-R-H131 polymorphism. Blood 1998 92: 1526-31.
    • (1998) Blood , vol.92 , pp. 1526-1531
    • Carlsson, L.E.1    Santoso, S.2    Baurichter, G.3    Kroll, H.4    Papenberg, S.5    Eichler, P.6
  • 72
    • 0031033922 scopus 로고    scopus 로고
    • Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/ platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
    • Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89: 370-5.
    • (1997) Blood , vol.89 , pp. 370-375
    • Arepally, G.1    McKenzie, S.E.2    Jiang, X.M.3    Poncz, M.4    Cines, D.B.5
  • 73
    • 0035469824 scopus 로고    scopus 로고
    • Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease
    • Trikalinos TA, Karassa FB, Ioannidis JP. Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease. Blood 2001; 98: 1634-5.
    • (2001) Blood , vol.98 , pp. 1634-1635
    • Trikalinos, T.A.1    Karassa, F.B.2    Ioannidis, J.P.3
  • 74
    • 7244239200 scopus 로고    scopus 로고
    • The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes
    • Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104: 2791-3.
    • (2004) Blood , vol.104 , pp. 2791-2793
    • Gruel, Y.1    Pouplard, C.2    Lasne, D.3    Magdelaine-Beuzelin, C.4    Charroing, C.5    Watier, H.6
  • 75
    • 0030611089 scopus 로고    scopus 로고
    • A novel polymorphism of Fc gamma RIIIa (CD 16) alters receptor function and predisposes to autoimmune disease
    • Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of Fc gamma RIIIa (CD 16) alters receptor function and predisposes to autoimmune disease, J Clin Invest 1997; 100: 1059-70.
    • (1997) J Clin Invest , vol.100 , pp. 1059-1070
    • Wu, J.1    Edberg, J.C.2    Redecha, P.B.3    Bansal, V.4    Guyre, P.M.5    Coleman, K.6
  • 76
    • 0034081558 scopus 로고    scopus 로고
    • Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia
    • Horsewood P, Kelton JG. Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia. Platelets 2000; 11: 23-7.
    • (2000) Platelets , vol.11 , pp. 23-27
    • Horsewood, P.1    Kelton, J.G.2
  • 77
    • 12444257703 scopus 로고    scopus 로고
    • Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia
    • Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Papenberg S, Schröder W, et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003; 13: 253-8.
    • (2003) Pharmacogenetics , vol.13 , pp. 253-258
    • Carlsson, L.E.1    Lubenow, N.2    Blumentritt, C.3    Kempf, R.4    Papenberg, S.5    Schröder, W.6
  • 78
    • 0027424433 scopus 로고
    • The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
    • The GUSTO Angiographic Investigators
    • The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Mod 1993; 329: 1615-22
    • (1993) N Engl J Med , vol.329 , pp. 1615-1622
  • 79
    • 19944375768 scopus 로고    scopus 로고
    • A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction
    • Marin F, Gonzalez-Conejero R, Lee KW, Corral J, Roldan V, Lopez F, et al. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2005; 45: 25-9.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 25-29
    • Marin, F.1    Gonzalez-Conejero, R.2    Lee, K.W.3    Corral, J.4    Roldan, V.5    Lopez, F.6
  • 80
    • 0032547326 scopus 로고    scopus 로고
    • Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
    • Heart and Estrogen/progestin Replacement Study (HERS) Research Group
    • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
    • (1998) JAMA , vol.280 , pp. 605-613
    • Hulley, S.1    Grady, D.2    Bush, T.3    Furberg, C.4    Herrington, D.5    Riggs, B.6
  • 81
    • 0035656115 scopus 로고    scopus 로고
    • Pharmacogenetics of estrogen replacement therapy
    • Herrington DM, Klein KP. Pharmacogenetics of estrogen replacement therapy. J Appl Physiol 2001; 91: 2776-84
    • (2001) J Appl Physiol , vol.91 , pp. 2776-2784
    • Herrington, D.M.1    Klein, K.P.2
  • 82
    • 0036202887 scopus 로고    scopus 로고
    • Interaction of hemostatic genetics with hormone therapy: New insights to explain arterial thrombosis in post-menopausal women
    • Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS, et al. Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in post-menopausal women. Cbest 2002; 121: 906-20.
    • (2002) Cbest , vol.121 , pp. 906-920
    • Braunstein, J.B.1    Kershner, D.W.2    Bray, P.3    Gerstenblith, G.4    Schulman, S.P.5    Post, W.S.6
  • 83
  • 84
    • 0028029477 scopus 로고
    • Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation
    • Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation. Lancet 1994: 369: 1453-7.
    • (1994) Lancet , vol.369 , pp. 1453-1457
    • Vandenbroucke, J.P.1    Koster, T.2    Briet, E.3    Reitsma, P.H.4    Bertina, R.M.5    Rosendaal, F.R.6
  • 87
    • 0032856643 scopus 로고    scopus 로고
    • Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C)
    • Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999; 84: 549-54.
    • (1999) Am J Cardiol , vol.84 , pp. 549-554
    • Glueck, C.J.1    Wang, P.2    Fontaine, R.N.3    Tracy, T.4    Sieve-Smith, L.5    Lang, J.E.6
  • 89
    • 0030992308 scopus 로고    scopus 로고
    • Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden
    • Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
    • (1997) Cancer , vol.79 , pp. 2024-2027
    • Weitz, I.C.1    Israel, V.K.2    Liebman, H.A.3
  • 90
    • 0029850530 scopus 로고    scopus 로고
    • A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
    • Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
    • (1996) Blood , vol.88 , pp. 3698-3703
    • Poort, S.R.1    Rosendaal, F.R.2    Reitsma, P.H.3    Bertina, R.M.4
  • 91
    • 0032543748 scopus 로고    scopus 로고
    • High risk of cerebral-vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives
    • Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Manucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338:1840-1.
    • (1998) N Engl J Med , vol.338 , pp. 1840-1841
    • Martinelli, I.1    Sacchi, E.2    Landi, G.3    Taioli, E.4    Duca, F.5    Manucci, P.M.6
  • 92
    • 0032976317 scopus 로고    scopus 로고
    • Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
    • Martinelli I, Taioli E, Bucciarelli P, Akhanan S, Manucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.
    • (1999) Arterioscler Thromb Vasc Biol , vol.19 , pp. 700-703
    • Martinelli, I.1    Taioli, E.2    Bucciarelli, P.3    Akhanan, S.4    Manucci, P.M.5
  • 93
    • 0037340390 scopus 로고    scopus 로고
    • Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk
    • Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-7.
    • (2003) Thromb Haemost , vol.89 , pp. 452-457
    • Vaya, A.1    Mira, Y.2    Mateo, J.3    Falco, C.4    Villa, P.5    Estelles, A.6
  • 94
    • 0035925154 scopus 로고    scopus 로고
    • Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
    • Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285: 906-13.
    • (2001) JAMA , vol.285 , pp. 906-913
    • Psaty, B.M.1    Smith, N.L.2    Lemaitre, R.N.3    Vos, H.L.4    Heckbert, S.R.5    LaCroix, A.Z.6
  • 95
    • 0035087879 scopus 로고    scopus 로고
    • Inter-action of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: A cross-sectional study of 275 hyperlipidemic women
    • Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Inter-action of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women. Metabolism 2001; 50: 360-5.
    • (2001) Metabolism , vol.50 , pp. 360-365
    • Glueck, C.J.1    Wang, P.2    Fontaine, R.N.3    Sieve-Smith, L.4    Lang, J.E.5
  • 96
    • 3242744485 scopus 로고    scopus 로고
    • DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy
    • Tempfer CB, Riener EK, Heller LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril 2004; 82: 132-7.
    • (2004) Fertil Steril , vol.82 , pp. 132-137
    • Tempfer, C.B.1    Riener, E.K.2    Heller, L.A.3    Huber, J.C.4    Muendlein, A.5
  • 98
    • 0037968650 scopus 로고    scopus 로고
    • Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction
    • Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003, 102: 25-30.
    • (2003) Blood , vol.102 , pp. 25-30
    • Reiner, A.P.1    Heckbert, S.R.2    Vos, H.L.3    Ariens, R.A.4    Lemaitre, R.N.5    Smith, N.L.6
  • 99
    • 2942720515 scopus 로고    scopus 로고
    • Beneficial cardiovascular pleiotropic effects of statins
    • Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-43.
    • (2004) Circulation , vol.109
    • Davignon, J.1
  • 102
    • 0035880668 scopus 로고    scopus 로고
    • The platelet P1(A2) and angiotensin-converting enzyme (ACE D) allele polymorphisms and the risk of recurrent events after acute myocardial infarction
    • Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, et al. The platelet P1(A2) and angiotensin-converting enzyme (ACE D) allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347-52.
    • (2001) Am J Cardiol , vol.88 , pp. 347-352
    • Bray, P.F.1    Cannon, C.P.2    Goldschmidt-Clermont, P.3    Moyé, L.A.4    Pfeffer, M.A.5    Sacks, F.M.6
  • 103
    • 2442465593 scopus 로고    scopus 로고
    • Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis
    • Tirado J, Soria JM, Oliver A, Souto JC, Santamaria A, Felices R, et al. Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899-904.
    • (2004) Thromb Haemost , vol.91 , pp. 899-904
    • Tirado, J.1    Soria, J.M.2    Oliver, A.3    Souto, J.C.4    Santamaria, A.5    Felices, R.6
  • 104
    • 0036840704 scopus 로고    scopus 로고
    • Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study
    • Zito F, Lowe GDO, Rumley A, McMahon AD, Humphries SE. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002; 165: 153-8.
    • (2002) Atherosclerosis , vol.165 , pp. 153-158
    • Zito, F.1    Lowe, G.D.O.2    Rumley, A.3    McMahon, A.D.4    Humphries, S.E.5
  • 106
    • 0032495541 scopus 로고    scopus 로고
    • The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
    • The Regression Growth Evaluation Statin Study Group
    • Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93.
    • (1998) N Engl J Med , vol.338 , pp. 86-93
    • Kuivenhoven, J.A.1    Jukema, J.W.2    Zwinderman, A.H.3    de Knijff, P.4    McPherson, R.5    Bruschke, A.V.6
  • 107
    • 10744219782 scopus 로고    scopus 로고
    • The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol and Recurrent Events study: No interaction with the response to pravastatin therapy and no effects on cardiovascular outcome
    • de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol and Recurrent Events study: No interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J Am Col Cardiol 2004; 43 854-7.
    • (2004) J Am Col Cardiol , vol.43 , pp. 854-857
    • de Grooth, G.J.1    Zerba, K.E.2    Huang, S.P.3    Tsuchihashi, Z.4    Kirchgessner, T.5    Belder, R.6
  • 108
    • 0033002576 scopus 로고    scopus 로고
    • Effect of stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
    • De Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, et al. Effect of stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852-6.
    • (1999) Am J Cardiol , vol.83 , pp. 852-856
    • De Maat, M.P.1    Jukema, J.W.2    Ye, S.3    Zwinderman, A.H.4    Moghaddam, P.H.5    Beekman, M.6
  • 109
    • 0038179661 scopus 로고    scopus 로고
    • Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events
    • Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, Van Der Wall EE, Reitsma PH, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107: 2416-21.
    • (2003) Circulation , vol.107 , pp. 2416-2421
    • Boekholdt, S.M.1    Agema, W.R.2    Peters, R.J.3    Zwinderman, A.H.4    Van Der Wall, E.E.5    Reitsma, P.H.6
  • 110
    • 0031836563 scopus 로고    scopus 로고
    • -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men-proposed role for an acute-phase reaction pattern of fibrinogen
    • de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, et al. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men-proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
    • (1998) Arterioscler Thromb Vasc Biol , vol.18 , pp. 265-271
    • de Maat, M.P.1    Kastelein, J.J.2    Jukema, J.W.3    Zwinderman, A.H.4    Jansen, H.5    Groenemeier, B.6
  • 111
    • 0034724089 scopus 로고    scopus 로고
    • The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction - A substudy of the Scandinavian Simvastatin Survival Study
    • Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction - a substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000; 101: 1366-71.
    • (2000) Circulation , vol.101 , pp. 1366-1371
    • Gerdes, L.U.1    Gerdes, C.2    Kervinen, K.3    Savolainen, M.4    Klausen, I.C.5    Hansen, P.S.6
  • 112
    • 0035852726 scopus 로고    scopus 로고
    • Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
    • Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103: 792-8.
    • (2001) Circulation , vol.103 , pp. 792-798
    • Zambon, A.1    Deeb, S.S.2    Brown, B.G.3    Hokanson, J.E.4    Brunzell, J.D.5
  • 113
    • 0141954076 scopus 로고    scopus 로고
    • Potential new targets for antithrombotic therapy
    • Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Des 2003; 9(28): 2367-74.
    • (2003) Curr Pharm Des , vol.9 , Issue.28 , pp. 2367-2374
    • Gruber, A.1    Hanson, S.R.2
  • 115
    • 1642265920 scopus 로고    scopus 로고
    • Use of sulfated fucans as anticoagulant and antithrombotic agents: Future perspectives
    • Mourao, PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Des 2004; 10(9): 967-81.
    • (2004) Curr Pharm Des , vol.10 , Issue.9 , pp. 967-981
    • Mourao, P.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.